SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ziopharm
ZIOP 0.866-0.9%Jan 26 3:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PLegee who wrote (7)2/2/2017 4:49:33 PM
From: The Ox  Read Replies (1) of 14
 
The run from $2 to $14 was pretty amazing but was way overdone, IMO. Had the stock simply gone up $1 or $1.50 per year since then, I doubt there would be anywhere near that many shorts. $4/2015, $5.50/2016, $7/2017....that would have been understandable.

Somewhat understandable that there are massive shorts, with the need to eventually raise more money. Also there are the outstanding warrants ....

If they are able to partner soon, at a reasonable price, they could "nuke" the shorts but from what I've read, not sure that's going to happen?

As you point out, a solid trial result may be all that's needed at this point in time....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext